Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

Anthony Cole Gallegos; Michael James Davis; Catherine N. Tchanque-Fossuo; Kaitlyn West; Angela Eisentrout-Melton; Thomas R. Peavy; Roy W. Dixon; Roma P. Patel; Sara Evona Dahle; Roslyn Rivkah Isseroff

doi:10.1089/wound.2019.0970

Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

Anthony Cole Gallegos, Michael James Davis, Catherine N. Tchanque-Fossuo, Kaitlyn West, Angela Eisentrout-Melton, Thomas R. Peavy, Roy W. Dixon, Roma P. Patel, Sara Evona Dahle, Roslyn Rivkah Isseroff

Dermatology

Research output: Contribution to journal › Article

Abstract

There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.

Original language	English (US)
Pages (from-to)	538-545
Number of pages	8
Journal	Advances in Wound Care
Volume	8
Issue number	11
DOIs	https://doi.org/10.1089/wound.2019.0970
State	Published - Nov 1 2019

Fingerprint

Keywords

absorption
adrenergic receptor
catecholamine
chronic wounds
glaucoma
timolol

ASJC Scopus subject areas

Emergency Medicine
Critical Care and Intensive Care Medicine

Cite this

Gallegos, A. C., Davis, M. J., Tchanque-Fossuo, C. N., West, K., Eisentrout-Melton, A., Peavy, T. R., Dixon, R. W., Patel, R. P., Dahle, S. E., & Isseroff, R. R. (2019). Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. Advances in Wound Care, 8(11), 538-545. https://doi.org/10.1089/wound.2019.0970

Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. / Gallegos, Anthony Cole; Davis, Michael James; Tchanque-Fossuo, Catherine N.; West, Kaitlyn; Eisentrout-Melton, Angela; Peavy, Thomas R.; Dixon, Roy W.; Patel, Roma P.; Dahle, Sara Evona; Isseroff, Roslyn Rivkah.

In: Advances in Wound Care, Vol. 8, No. 11, 01.11.2019, p. 538-545.

Research output: Contribution to journal › Article

Gallegos, Anthony Cole ; Davis, Michael James ; Tchanque-Fossuo, Catherine N. ; West, Kaitlyn ; Eisentrout-Melton, Angela ; Peavy, Thomas R. ; Dixon, Roy W. ; Patel, Roma P. ; Dahle, Sara Evona ; Isseroff, Roslyn Rivkah. / Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. In: Advances in Wound Care. 2019 ; Vol. 8, No. 11. pp. 538-545.

@article{5d76169b9d5c45958cc44a9350e94dc2,

title = "Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds",

abstract = "There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.",

keywords = "absorption, adrenergic receptor, catecholamine, chronic wounds, glaucoma, timolol",

author = "Gallegos, {Anthony Cole} and Davis, {Michael James} and Tchanque-Fossuo, {Catherine N.} and Kaitlyn West and Angela Eisentrout-Melton and Peavy, {Thomas R.} and Dixon, {Roy W.} and Patel, {Roma P.} and Dahle, {Sara Evona} and Isseroff, {Roslyn Rivkah}",

year = "2019",

month = nov

day = "1",

doi = "10.1089/wound.2019.0970",

language = "English (US)",

volume = "8",

pages = "538--545",

journal = "Advances in Wound Care",

issn = "2162-1918",

publisher = "Mary Ann Liebert Inc.",

number = "11",

}

TY - JOUR

T1 - Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

AU - Gallegos, Anthony Cole

AU - Davis, Michael James

AU - Tchanque-Fossuo, Catherine N.

AU - West, Kaitlyn

AU - Eisentrout-Melton, Angela

AU - Peavy, Thomas R.

AU - Dixon, Roy W.

AU - Patel, Roma P.

AU - Dahle, Sara Evona

AU - Isseroff, Roslyn Rivkah

PY - 2019/11/1

Y1 - 2019/11/1

N2 - There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.

AB - There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.

KW - absorption

KW - adrenergic receptor

KW - catecholamine

KW - chronic wounds

KW - glaucoma

KW - timolol

UR - http://www.scopus.com/inward/record.url?scp=85073879406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073879406&partnerID=8YFLogxK

U2 - 10.1089/wound.2019.0970

DO - 10.1089/wound.2019.0970

M3 - Article

AN - SCOPUS:85073879406

VL - 8

SP - 538

EP - 545

JO - Advances in Wound Care

JF - Advances in Wound Care

SN - 2162-1918

IS - 11

ER -

Access to Document

10.1089/wound.2019.0970